Traws Pharma
TRAW
Traws Pharma (TRAW) earnings history
Most recent quarter
- Fiscal period
- Q2 2025
- Period end
- Jun 30, 2025
- EPS actual
- −$0.11
- EPS estimate
- −$8.75
- EPS surprise
- +98.74%
- Revenue surprise
- +4455.00%
- Revenue
- $2.7M
- Revenue estimate
- $60,000.00
- Reported
- Aug 14, 2025
Earnings history
| Period | Reported | EPS estimate | EPS actual | Surprise | Revenue | Filing |
|---|---|---|---|---|---|---|
| Q2 2025 | Aug 14, 2025 | −$8.75 | −$0.11 | +98.74% | $2.7M | SEC |
| Q1 2025 | May 15, 2025 | −$8.04 | $2.09 | +126.00% | $57,000.00 | SEC |
| Q4 2024 | Mar 31, 2025 | −$9.55 | $101.35 | +1161.26% | $56,000.00 | SEC |
| Q3 2024 | Nov 14, 2024 | −$6.25 | −$8.81 | −40.96% | $57,000.00 | SEC |
| Q2 2024 | Aug 15, 2024 | −$6.25 | −$121.75 | −1848.00% | $57,000.00 | SEC |
| Q1 2024 | May 15, 2024 | −$5.88 | −$6.00 | −2.13% | $56,000.00 | SEC |
| Q4 2023 | Apr 1, 2024 | −$6.33 | −$4.75 | +25.00% | $56,000.00 | SEC |
| Q3 2023 | Nov 14, 2023 | −$7.25 | −$5.75 | +20.69% | $57,000.00 | SEC |
| Q2 2023 | Aug 10, 2023 | −$7.81 | −$5.00 | +36.00% | $57,000.00 | SEC |
| Q1 2023 | May 15, 2023 | −$7.44 | −$7.00 | +5.88% | $56,000.00 | SEC |
| Q4 2022 | Mar 16, 2023 | −$6.94 | −$6.50 | +6.31% | $46,000.00 | SEC |
| Q3 2022 | Nov 14, 2022 | −$5.31 | −$6.50 | −22.35% | $57,000.00 | — |
| Q2 2022 | Aug 11, 2022 | −$4.94 | −$4.75 | +3.80% | $57,000.00 | — |
| Q1 2022 | May 11, 2022 | −$4.69 | −$5.00 | −6.67% | $56,000.00 | — |
| Q4 2021 | Mar 17, 2022 | −$6.75 | −$4.25 | +37.04% | $56,000.00 | — |
| Q3 2021 | Nov 12, 2021 | −$8.17 | −$5.50 | +32.65% | $57,000.00 | — |
| Q2 2021 | Aug 12, 2021 | −$7.13 | −$6.75 | +5.26% | $57,000.00 | — |
| Q1 2021 | May 17, 2021 | −$11.25 | −$7.50 | +33.33% | $56,000.00 | — |
| Q4 2020 | Mar 11, 2021 | −$12.50 | −$15.00 | −20.00% | $51,000.00 | — |
| Q3 2020 | Nov 12, 2020 | −$12.50 | −$11.25 | +10.00% | $66,000.00 | — |
Quarterly revenue
Frequently asked questions
When did Traws Pharma (TRAW) last report earnings?
Traws Pharma last reported on Aug 14, 2025, covering fiscal Q2 2025.
Did TRAW beat earnings estimates?
Yes. Traws Pharma reported EPS of −$0.11 for Q2 2025 against a −$8.75 estimate — a 98.74% beat.
How much revenue did TRAW report last quarter?
Traws Pharma reported $2.7M in revenue for Q2 2025, against a consensus estimate of $60,000.00.
Earnings figures may be restated, revised or corrected by the issuer. Past results do not indicate future performance.
This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.